Obermatt
See Similar Stocks →

Flags

Earnings warning

Lexicon Pharmaceuticals

NAQ:LXRX · US5288723027
PharmaceuticalsSmall

360

28
Medium confidence — indicative
Profit price—
Cash yield1
Price/Sales8
EV / Gross Profit18
Price/Book19
Return on Capital29
Return on Equity35
EBIT Margin11
Gross Profitability52

Cash truth not applicable for financial companies.

Sales growth11
Profit growth20
Reinvestment42
Price momentum94
Debt load54
Debt serviceability65
Liquidity46
Analyst ratings30
Opinion Changes50
Price Target Upside74
Market mood27
Value Creation17/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Lexicon Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1995
Employees185
Websitelexpharma.com
ISINUS5288723027
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesCardiovascularPain ManagementNeurologyObesityNeuroscienceCentral Nervous SystemBioinformaticsBiotechnologyMedicalPharmaceutical

Description

Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is devoting most of its resources to the research and development of the company's most advanced drug candidates, as well as the commercialization of its approved dru…

Analysis

Middle-of-the-road

Lexicon Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 17/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
9
2026

All-time high

9

Jun 2026

All-time low

1

Mar 2026

Average rank

5

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
76
—
—
—
Price/Book
19
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
19
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Lexicon Pharmaceuticals with its peers
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
MannKind
NMQ:MNKD
24
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kestra Medical Technologies
NSQ:KMTS
21
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →